Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

The FDA Oncologic Drugs Advisory Committee voted against recommending panobinostat plus bortezomib and dexamethasone for patients with previously treated multiple myeloma.

Methods: This phase I trial explores the safety, tolerability, and maximum tolerated dose (MTD) of a 3-week cycle of escalating panobinostat doses taken orally on days 1, 3, and 5 followed by ...

The combination of panobinostat and capecitabine is well-tolerated at the recommended doses of 30 mg twice weekly continuously and 1,000mg/m 2 BID × 14 days every 21 days. Patient accrual will ...